697 results on '"Angulo, Paul"'
Search Results
52. Nonalcoholic Fatty Liver Disease
53. Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study
54. Cholangiocarcinoma in pregnancy: A case report
55. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease
56. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis
57. To detect or not to detect, that is the question: An approach to breast cancers not visible on digital breast tomosynthesis
58. Value of a computer-assisted detection (CAD) system designed for digital mammography (DM) in the diagnosis of breast cancer assessed by DM and digital breast tomosynthesis (DBT)
59. Light to Moderate Alcohol Consumption Is Associated With Lower Frequency of Hypertransaminasemia
60. Cholangiocarcinoma in Young Individuals With and Without Primary Sclerosing Cholangitis
61. Overlap of Autoimmune Hepatitis and Primary Biliary Cirrhosis: Long-Term Outcomes
62. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
63. Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis
64. Abnormal Hepatic Biochemistries in Patients With Inflammatory Bowel Disease
65. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis
66. NAFLD in children: A prospective clinical-pathological study and effect of lifestyle advice
67. Nonalcoholic fatty liver disease and liver transplantation
68. The effect of the metabolic syndrome, hepatic steatosis and steatohepatitis on liver fibrosis in hereditary hemochromatosis
69. The Bulge, Booze, and the Liver
70. Alendronate Improves Bone Mineral Density in Primary Biliary Cirrhosis: A Randomized Placebo-Controlled Trial*#
71. Nonalcoholic fatty liver disease
72. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease
73. Secondary Sclerosing Cholangitis: A Comparison to Primary Sclerosing Cholangitis
74. Insulin Resistance, Auto-antibodies, and Nonalcoholic Fatty Liver Disease Response to Letter
75. Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease
76. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study
77. Mycophenolate Mofetil for the Treatment of Primary Sclerosing Cholangitis
78. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease
79. Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae?
80. Treatment of nonalcoholic steatohepatitis: Antioxidants or insulin sensitizers?
81. A Pilot Trial of Pentoxifylline in Nonalcoholic Steatohepatitis
82. The Prevalence of Autoantibodies and Autoimmune Hepatitis in Patients with Nonalcoholic Fatty Liver Disease
83. Open-Label Pilot Study of Tetracycline in the Treatment of Primary Biliary Cirrhosis
84. Incidence and Risk Factors for Cholangiocarcinoma in Primary Sclerosing Cholangitis
85. Ursodeoxycholic Acid and Long-Term Survival in Primary Biliary Cirrhosis
86. Association of Primary Biliary Cirrhosis and Rheumatoid Arthritis
87. When is Liver Biopsy Needed in the Diagnosis of Primary Biliary Cirrhosis?
88. Medical Progress: Nonalcoholic Fatty Liver Disease
89. Non-alcoholic fatty liver disease
90. Tumor necrosis factor-α and transforming growth factor-β reflect severity of liver damage in primary biliary cirrhosis
91. Treatment of Nonalcoholic Fatty Liver: Present and Emerging Therapies
92. Is there a role for liver biopsy in primary sclerosing cholangitis?
93. Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis
94. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system
95. Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis
96. Serum autoantibodies in patients with primary sclerosing cholangitis
97. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial
98. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid
99. Pathologic response to neoadjuvant therapy with nabpaclitaxel plus carboplatin followed by anthracycline regimen in triple-negative breast cancer.
100. Diagnostic value of halo sign in young women (aged 45 to 49 years) in a breast screening programme with synthesized 2D mammography
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.